First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma

References

• Alexander HR Jr, Burk AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016;7:79–86.
   PubMed Web of Science ®Google Scholar
• Gemba K, Fujimoto N, Kato K, et al. National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci. 2012;103:483–490.
   PubMed Web of Science ®Google Scholar
• Daya D, McCaughey WT. Pathology of the peritoneum: a review of selected topics. Semin Diagn Pathol. 1991;8:277–289.
   PubMed Web of Science ®Google Scholar
• Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133:1317–1331.
   PubMed Web of Science ®Google Scholar
• Miles JM, Hart WR, McMahon JT. Cystic mesothelioma of the peritoneum. Report of a case with multiple recurrences and review of the literature. Cleve Clin Q. 1986;53:109–114.
   PubMedGoogle Scholar
• Fasola G, Puglisi F, Follador A, et al. Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report. BMC Cancer. 2006;6:289.
   PubMed Web of Science ®Google Scholar
• Britton M. The epidemiology of mesothelioma. Semin Oncol. 2002;29:18–25.
   PubMed Web of Science ®Google Scholar
• Neumann V, Günthe S, Mülle KM, et al. Malignant mesothelioma–German mesothelioma register 1987-1999. Int Arch Occup Environ Health. 2001;74:383–395.
   PubMed Web of Science ®Google Scholar
• Kindler HL. Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book. 2013;182–188.
   PubMedGoogle Scholar
• Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011;103:822–831.
   PubMed Web of Science ®Google Scholar
• Manzini Vde P, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21:348–353.
   PubMed Web of Science ®Google Scholar
• Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–4567.
   PubMed Web of Science ®Google Scholar
• Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22:1680–1685.
   PubMed Web of Science ®Google Scholar
• Raza A, Huang W, Takabe K. Advances in the management of peritoneal mesothelioma. World J Gastroenterol. 2014;20:11700–11712.
   PubMed Web of Science ®Google Scholar
• Deraco M, Bartlett D, Kusamura S, et al. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98:268–272.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Armato SG, Kindler HL. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer. 2006;52:141–148.
   PubMed Web of Science ®Google Scholar
• Plathow C, Klopp M, Thieke C. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol. 2008;18:1635–1643.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol. 2006;24:4587–4593.
   PubMed Web of Science ®Google Scholar
• Francis RJ, Byrne MJ, Van Der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48:1449–1458.
   PubMed Web of Science ®Google Scholar
• Veit-Haibach P, Schaefer NG, Steinert HC, et al. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer. 2010;67:311–317.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol. 2002;29:51–61.
   PubMed Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–1782.
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Key CR, Hassan R. Clinical presentation and natural history of mesothelioma: abdominal. In: Pass HI, Vogelzang NJ, Carbone M, editors. Malignant mesothelioma. New York: Springer; 2005. p. 391–401.
   Google Scholar
• Rodríguez D, Cheung MC, Housri N, et al. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol. 2000;99:51–57.
   Web of Science ®Google Scholar
• Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:1686–1693.
   PubMed Web of Science ®Google Scholar
• Yan TD, Popa E, Brun EA, et al. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg. 2006;93:1536–1542.
   PubMed Web of Science ®Google Scholar
• Kerrigan SA, Turnnir RT, Clement PB, et al. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer. 2002;94:378–385.
   PubMed Web of Science ®Google Scholar
• Valente K, Blackham AU, Levine E, et al. A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype. Am J Surg Pathol. 2016;40:1243–1248.
   PubMed Web of Science ®Google Scholar
• Patel NP, Taylor CA, Levine EA, et al. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol. 2007;128:414–422.
   PubMed Web of Science ®Google Scholar
• Cheung M, Kadariya Y, Talarchek J, et al. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer Lett. 2015;369:261–265.
   PubMed Web of Science ®Google Scholar
• Boyde AM, Attanoos RL. Sister Mary Joseph’s nodule in malignant peritoneal mesothelioma. Histopathology. 2003;43:303–304.
   PubMed Web of Science ®Google Scholar
• Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma−results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–218.
   PubMed Web of Science ®Google Scholar
• Saxena A, Chua TC. Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma. Lung Cancer. 2009;66:269–270.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40–46.
   PubMed Web of Science ®Google Scholar
• Lainakis G, Zagouri F, Kastritis E, et al. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Tumori. 2011;97:25–29.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017 Jan;29:S0748-7983(17)30059-8.
   Google Scholar
• Domènech-Vilardell A, Rasiej MJ, Taub RN, et al. Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma. Q J Nucl Med Mol Imaging. 2016;60:54–61.
   PubMed Web of Science ®Google Scholar